|
| Press Releases |
|
 |
|
| Tuesday, October 24, 2017 |
|
|
Singapore eDevelopment's Global BioLife develops Low-GI Modified Sugar |
| SGX-listed Singapore eDevelopment Ltd ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife Inc. has developed a breakthrough low-calorie, low glycemic index, natural, modified sugar Laetose -- which has the potential to affect the world's sugar market. more info >> |
|
| Tuesday, August 15, 2017 |
|
|
Singapore eDevelopment's Global BioLife and Chemia Corp. to develop 3F suite of Functional Fragrances |
| Singapore eDevelopment Ltd (SeD; SGX:SGE) has announced that its indirect subsidiary, Global BioLife Inc., is collaborating with U.S.-based Chemia Corporation to develop specialised fragrances which can counter mosquito-borne diseases, diminish stress and anxiety, and act in anti-viral medical applications. more info >> |
|
| Thursday, June 15, 2017 |
|
|
First-Year Performance of Global Systematic Multi-Strategy Fund |
| The Board of Directors of Singapore eDevelopment Ltd ("SeD") wishes to announce that its Global Systematic Multi-Strategy Fund ("GSMS Fund") managed by Hengfai Asset Management Pte Ltd ("HFAM"), a wholly owned subsidiary of SeD's investment-arm SeD Capital Pte Ltd, achieved a gross and net return of 15% and 10%, respectively, in its first year of operation. more info >> |
|
| Monday, May 22, 2017 |
|
|
Singapore eDevelopment's Global BioLife Initiates Research on New Universal Drug Platform |
| Singapore eDevelopment Ltd ("SeD"), through its subsidiary Global BioLife Inc. ("Global BioLife"), has initiated advanced research of a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee, Mr Daryl Thompson. more info >> |
|
|
Singapore eDevelopment Subsidiary Initiates Research on New Universal Drug Platform |
| Singapore eDevelopment Limited ("SeD") subsidiary Global BioLife Inc. has initiated advanced research of a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
CITIC Telecom CPC Wins Two Awards, Celebrating 'Innovation Never Stops' for 25 Years, recognizing Cybersecurity & Innovation Excellence
Feb 9, 2026 13:28 HKT/SGT
|
|
|
中信國際電訊CPC榮獲兩大獎項 慶祝創新不斷廿五載 彰顯網絡安全與持續創新實力
Feb 9, 2026 13:11 HKT/SGT
|
|
|
JCB Announces Collaboration with Resorts World Sentosa in Singapore
Feb 9, 2026 14:00 JST
|
|
|
中信国际电讯CPC荣获两大奖项 庆祝创新不断廿五载 彰显网络安全与持续创新实力
Feb 9, 2026 12:48 HKT/SGT
|
|
|
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Feb 9, 2026 11:00 JST
|
|
|
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group
Feb 8, 2026 23:30: JST
|
|
|
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group
Feb 8, 2026 23:30 HKT/SGT
|
|
|
Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.
Feb 7, 2026 05:45 HKT/SGT
|
|
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司首次入股 涉資約1億美元
Feb 6, 2026 16:56 HKT/SGT
|
|
|
歌礼制药-B（01672）获新加坡政府投资公司首次入股 涉资约1亿美元
Feb 6, 2026 16:50 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
トヨタ、役員人事を発表
Feb 6, 2026 16:00: JST
|
|
|
牧原股份港股上市：全球生豬养殖龍頭 價值成長兼具
Feb 6, 2026 15:08 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
